Dr. Christopher J. Welty, MD

Dr. Welty practices at Bass Medical Group in Oakland, California.

Dr. Welty's NPI, 1750571360, was assigned on July 30, 2007. Dr. Welty graduated from Vanderbilt University School Of Medicine in 2007. Dr. Welty holds California license A126313.

Dr. Welty's primary practice is Bass Medical Group, at 3300 Webster St, Oakland, CA 94609 in Alameda County. The practice phone is (925) 932-6330.

Dr. Welty's primary practice is Bass Medical Group in Oakland, California. Dr. Welty is also affiliated with Alta Bates Summit Medical Center. The medical group on file is BASS Medical Group. Dmand AI also links Dr. Welty to 4 more hospitals, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Welty practices, 7 sites in all. Vendor and product names are available with a free account.

Urology is Dr. Welty's primary specialty in the NPI Registry, under taxonomy code 208800000X. Dr. Welty is board certified in urology by the American Board of Urology. Dmand AI has Dr. Welty's licenses on file in 2 states: California and Washington.

Dmand AI lists bladder disease, enlarged prostate, enlarged prostate transurethral surgery (TURP), erectile dysfunction, kidney cysts, kidney removal surgery, kidney stone disease and prostate cancer among the conditions Dr. Welty treats.

CMS data shows 5,151 Medicare services from Dr. Welty across 23 procedure codes in 2024, for 910 Medicare patients. Medicare paid $350,672 for them.

CMS counts 910 Medicare patients who saw Dr. Welty in 2024. The largest group is 75 to 84, with 402 patients. 75% of them have high cholesterol, and 72% have high blood pressure. 8% are also on Medicaid. Their average risk score is 1.12, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Welty's median patient age at 73, with 16% women.

In 2024, Dr. Welty wrote 2,562 Medicare Part D claims for 700 patients. 93% of them were for generic drugs. CMS names the drug for 2,427 of them, across 29 drugs with 11 or more claims each, at $246,257 in total drug cost. In 2023, CMS named 2,327 claims across 27 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 91 out of 100 for Dr. Welty for performance year 2024, reported through an alternative payment model (APM). Dr. Welty accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Welty as offering telehealth. CMS counts 19 procedures of prostate resection by Dr. Welty, more than 79% of the clinicians it reports for that procedure.

Dmand AI links 23 papers to Dr. Welty, published from 2010 to 2021. 2014 was the busiest year, with 5. The most frequent topics are Prostatic Neoplasms, Watchful Waiting and Biomarkers, Tumor. Dr. Welty has published most often in J Urol. Dr. Welty's most frequent co-authors are Peter R. Carroll, MD, Matthew R. Cooperberg, MD and Hao G. Nguyen, MD.

CMS Open Payments shows 495 general payments to Dr. Welty from 78 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 87% of the total. Astellas Pharma US Inc paid the most, $1,321.

Dr. Welty graduated from Vanderbilt University School Of Medicine in 2007.

Dr. Welty is in network with 14 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Elevance. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.